title: Fc-gamma receptors: Attractive targets for autoimmune drug discovery searching for intelligent therapeutic designs.
abstract: Autoantibody immune complexes (ICs) mediate pathogenesis in multiple autoimmune diseases via direct interference with target function, complement fixation, and interaction with Fc-gamma receptors (FcγRs). Through high avidity interactions, ICs are able to crosslink low affinity FcγRs expressed on a wide variety of effector cells, leading to secretion of pro-inflammatory mediators and inducing cytotoxicity, ultimately resulting in tissue injury. Given their relevance in numerous autoimmune diseases, FcγRs have been considered as attractive therapeutic targets for the last three decades. However, a limited number of investigational drug candidates have been developed targeting FcγRs and only a few approved therapeutics have been associated with impacting FcγRs. This review provides a historical overview of the different therapeutic approaches used to target FcγRs for the treatment of autoimmune and inflammatory diseases.
authors: Momenta Pharmaceuticals, 675 West Kendall Street, Cambridge, MA 02142, USA.
authors: Carlos J
authors: CJ
authors: Bosques
authors: Momenta Pharmaceuticals, 675 West Kendall Street, Cambridge, MA 02142, USA. Electronic address: tmanning@momentapharma.com.
authors: Anthony M
authors: AM
authors: Manning
mesh_terms: D000936:Antigen-Antibody Complex / Q000276:immunology; D001323:Autoantibodies / Q000276:immunology; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology; D055808:Drug Discovery; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D017452:Receptors, IgG / Q000037:antagonists & inhibitors*
chemical_list: D000936:Antigen-Antibody Complex; D001323:Autoantibodies; D017452:Receptors, IgG
keywords: Autoimmune disease; Fc-gamma receptors; Immune complex; Therapeutics